French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that it has received European Commission approval for VaxRabeo, its next-generation rabies vaccine, for pre-exposure and post-exposure prophylaxis in patients of all ages.
This approval marks the vaccine's first marketing authorisation and follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use in September 2026.
Manufactured using Vero-cell technology, VaxRabeo is designed to reduce the risk of allergic reactions and offers improved thermostability and a longer shelf life compared with Sanofi's existing rabies vaccines.
The approval is supported by clinical studies comparing VaxRabeo with Sanofi's existing vaccines, Verorab and Imovax Rabies, across different age groups and recommended vaccination schedules. Results showed comparable protective antibody levels in pre-exposure settings, similar immunogenicity in post-exposure treatment and strong booster responses, with no significant safety concerns.
Rabies remains a major global public health challenge, affecting 150 countries and causing approximately 59,000 deaths annually, according to World Health Organization estimates. Although the disease is preventable through vaccination, it is almost always fatal once symptoms develop.
Northwest Biotherapeutics and NHSBT collaborate to support production of DCVax-L
Bavarian Nordic reports purchases under share buy-back programme
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
ABEC opens new manufacturing facility in Wilson, NC
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
EpiVax introduces AI-enhanced models for immunogenicity prediction